• Publications
  • Influence
Improved survival with ipilimumab in patients with metastatic melanoma.
TLDR
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Expand
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
TLDR
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Expand
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
TLDR
Evaluated data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment, as well as across multiple cancer types. Expand
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
TLDR
Systematic criteria, designated immune-related response criteria, were defined in an attempt to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by Response Evaluation Criteria in Solid Tumors or WHO criteria. Expand
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
TLDR
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. Expand
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
TLDR
Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipILimumab alone, and in patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. Expand
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
TLDR
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipILimumab monotherapy. Expand
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
TLDR
Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilicumab and a BRAF inhibitor. Expand
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
TLDR
Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation. Expand
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
TLDR
Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC, and overall survival, response durability, and long-term safety were reported. Expand
...
1
2
3
4
5
...